leisure time -WSS

leisure time

author：explore 2025-09-14 21:56:38 - browse：4612

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Cognito secures funding to test medical device for Alzheimer's

explore

WSS

Some medical students still think black patients feel less pain

Novo Nordisk to expand supply of Wegovy for U.S. patients

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Vertigo drug brings hope for rare neuron disorder, Niemann

The Bio Revolution is changing business and society

Lawsuit challenges CMS nursing home minimum staffing rule

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Cancer drug shortages should be causing more outrage

Vertigo drug brings hope for rare neuron disorder, Niemann

The cancer drug shortage isn’t new — and neither are the solutions

A $475,000 price tag for a new cancer drug: crazy or meh?

Wildfire smoke exposes gaps in outdoor worker protections

Do digital therapeutics have a future in medicine?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New research sheds light on how often breast cancer is overdiagnosed

FDA approval of Sarepta Duchenne genetic therapy gives me hope

SAMSHA loosens regulations on methadone treatment centers

entertainment

The real point of Kenneth Smith’s execution by nitrogen gas

Time to name cancers by genetics, not organ of origin, expert says

Stroke rates rising, especially in working

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

General Catalyst, Summa Health deal will turn on physician buy

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

explore

hotspot

hotspot

focus